Impact of Sjogren’s syndrome on Parkinson’s disease: A nationwide case-control study

Ming-Chi Wu¹,²,³*, Xun Xu²,⁴*, Shan-Ming Chen¹,⁵, Yeu-Sheng Tyan¹,²,⁶, Jeng-Yuan Chiou⁷, Yu-Hsun Wang⁸, Li-Chi Lin⁹,¹⁰, Chyong-Mei Chen¹¹,¹², James Cheng-Chung Wei¹,⁹,¹³

¹ School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ² Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan, ³ Department of Medical Informatics, Chung Shan Medical University, Taichung, Taiwan, ⁴ Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China, ⁵ Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁶ School of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan, ⁷ School of Health Policy and Management, Chung Shan Medical University, Taichung, Taiwan, ⁸ Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁹ Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital; Taichung, Taiwan, ¹⁰ Department of Statistics, Oklahoma state University, Stillwater, United States of America, ¹¹ Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, ¹² School of Medicine, National Yang-Ming University, Taipei, Taiwan, ¹³ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

These authors contributed equally to this work.

* jccwei@gmail.com

Abstract

Objective
To investigate whether Sjogren’s syndrome would have an influence on the development of Parkinson’s disease.

Methods
A population-based case-control study was conducted. Participants consisted of 7716 subjects with newly diagnosed Parkinson’s disease and a population of 75129 matched control subjects between 2000 and 2010. We measured the risk of Parkinson’s disease in association with Sjogren’s syndrome by using adjusted odds ratios.

Results
A total of 143 Parkinson’s disease subjects (1.9%) and 893 control subjects (1.2%) suffered from Sjogren’s syndrome (p < 0.001). The crude odds ratio for Parkinson’s disease among subjects with Sjogren’s syndrome was 1.56 (95% CI 1.30–1.86; p < 0.01). After adjustment for potential confounders which have been proposed that would increase the risk of development of Parkinson’s disease, Sjogren’s syndrome was found to be significantly associated with the risk of Parkinson’s disease with an odds ratio of 1.37 (95% CI 1.15–1.65; p < 0.01).
Conclusion
This study preliminarily proposed that Sjogren’s syndrome was significantly associated with an increased risk of Parkinson’s disease.

Introduction
Parkinson’s disease (PD), known as a common neurodegenerative disease, impacts on people in middle to older age group, and is characterized by rigidity, bradykinesia, resting tremor and postural instability [1–3]. The prevalence of PD per 100,000 of population is 84.8 to 147.7 and the incidence of PD is 28.8 to 35.3 of 100,000 per year in Taiwan [4]. With advance of the disease, various problems, such as cognitive dysfunction and living barrier, are present to disturb the PD patients and their families, which may increase the burden of society and health care system [5,6]. Thus, for the purpose of preventing and early detecting PD, investigation of risk factors for PD is becoming an important study issue nowadays.

As previous studies revealed, patients with diabetes, hypertension, end-stage renal disease and dyslipidemia would tend to increase the risk of PD [7–9]. Moreover, atrial fibrillation has also been proven to be related to the generation of PD [10]. It was mentioned by some studies that autoimmune diseases, for instance rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, osteoarthritis and vasculitis, were well-recognized risk factors of PD because of the neurologic abnormalities caused by immune damage [11–16]. In addition to these autoimmune factors, few studies introduced that Sjogren’s syndrome (SS) was connected with PD nowadays [17,18].

SS is an autoimmune disease which can enroll multisystem and cause impairment of exocrine glands, leading to dry eyes, dry mouth and salivary gland enlargement. The prevalence of SS is 43.69 to 77.94 per 100 000. The incidence of SS was 4.98 to 8.86 of 100,000 per year in Taiwan [19]. Although the definite cause of SS remains obscure, previous study proposed that lymphocytic infiltration and immunologically mediated mechanisms were connected with the occurrence of SS [20]. When the lymphocytes and immunoreactive proteins infiltrate the nervous systems, some neurological impairment would appear. According to some researches, approximately 31% patients with SS would suffer from the central nervous system (CNS) impairment [21].

Although several studies have investigated the association between SS and PD, the sample sizes of these studies were too small to gain a convincing result [17,18]. Therefore, the purpose of this study is to explore whether SS is associated with the generation of PD by conducting a case-control study based on a nationwide longitudinal population-based database.

Materials and methods
1. Data source
This study used Longitudinal Health Insurance Database (LHID) from 2000 to 2010 which contained 1 million beneficiaries who were randomly sampled from the original National Health Institutes Research Database (NHIRD) beneficiaries in Taiwan. The NHIRD was launched in 1995 and there are approximately 27.38 million individuals involved in this registry, which enrolls more than 99% of the total population in Taiwan nowadays. All the registrations and claims data of the 1 million beneficiaries are contained in the database, including laboratory and diagnostic tests, drug prescriptions, ambulatory and inpatient care and the
International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes.

2. Population selection

This population-based case-control study was approved by the Chung Shan Medical University Hospital institutional review board (CSMU No: CS15134). There were two groups enrolled in this study, one was made up from the subjects with newly diagnosed PD and the other was the control group without PD. Subjects with at least twice ambulatory or once admission diagnosis of PD from January 1, 2000 to December 31, 2010 were included in the case group, which contained 11189 of the 1 million beneficiaries. The diagnosis and code (ICD-9-CM 332) were made by neurologists according to the Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria [22]. We excluded the subjects with diagnosis of PD before 2000 and age younger than 50 years old, resulting in 8443 in the Parkinson’s disease group. The flowchart of this study was shown in Fig 1.

The control group was derived from the remain beneficiaries who had never been diagnosed of PD between 2000 and 2010 in LHID. The selected subjects in control group were matched with those in case group by ten control subjects per study subject according to age, gender and index date. Finally, we got 7716 subjects in case group and 75129 subjects in control group.

3. Baseline variables

The baseline variables of demography were age and gender. Other diseases and affecting factors diagnosed before the diagnosis of PD were also observed, and enrolled with at least twice ambulatory or once inpatient diagnosis, such as RA (ICD-9-CM 714.0), ankylosing spondylitis (ICD-9-CM 720.2), SS (ICD-9-CM 710.2), SLE (ICD-9-CM 710.0), psoriasis (ICD-9-CM 696), osteoarthritis (ICD-9-CM 715), diabetes (ICD-9-CM 250, 357.2, 362.0, 366.41), hypertension (ICD-9-CM 401–405, 437.31), atrial fibrillation (ICD-9-CM 427.31), end-stage renal disease (ICD-9-CM 585), dyslipidemia (ICD-9-CM 427.31), and vasculitis (ICD-9-CM 447.6, 437.4). The diagnosis and code (ICD-9-CM 710.2) were made by rheumatology according to the European classification criteria for Sjögren’s syndrome of 2002 [19]. The data collection of the diseases or affect factor all before the index date.

4. Statistical analysis

In order to compare the demographic characteristics and affecting factors between case group and control group, Fisher’s exact test was applied for continuous variables, and Pearson’s chi-squared test was applied for categorical variables. The significant factors were then used to obtain the odds ratios (ORs) and 95% confidence intervals (CIs) by performing conditional logistic regression. The crude ORs and 95% CIs would firstly be determined for univariate analysis, and then the adjusted ORs and 95% CIs would be obtained after adjusting other affecting factors which would be considered as confounding variables. All the Statistical analysis was performed by utilizing the SPSS 18 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as a p value of less than 0.05.

Results

After matching the non-PD subjects with the PD subjects, there was no significant differences found in age (p = 0.23) and gender (p = 0.76). The mean age of 7716 PD subjects was 72.8 ± 9.0 years, including 3898 (50.5%) women and 3818 (49.5%) men. And the mean age of
75129 non-PD subjects was 72.7 ± 9.0 years, including 38094 (50.7%) women and 37035 (49.3%) men.

The difference on baseline variables between case group and control group was shown in Table 1. 143 of the 7716 PD subjects had SS, which suggested a significant difference as compared with the control group (p < 0.001). In addition, the subjects in study group were more likely to have comorbid ankylosing spondylitis (p = 0.009), osteoarthritis (p < 0.001), diabetes (p < 0.001), hypertension (p < 0.001), atrial fibrillation (p < 0.001), end-stage renal disease (p < 0.001), dyslipidemia (p < 0.001) and vasculitis (p = 0.001).

The association between affecting factors and the risk of PD was illustrated in Table 2. For univariate analysis, SS was significantly associated with increased risk of PD (OR, 1.56; 95% CI 1.30–1.86, p < 0.01). On the other hand, ankylosing spondylitis (OR, 1.41; 95% CI 1.08–1.84, p < 0.01).
p < 0.05), osteoarthritis (OR, 1.60; 95% CI 1.53–1.69, p < 0.01), diabetes (OR, 1.61; 95% CI 1.53–1.69, p < 0.01), hypertension (OR, 1.99; 95% CI 1.89–2.10, p < 0.01), atrial fibrillation (OR, 1.42; 95% CI 1.27–1.59, p < 0.01), end-stage renal disease (OR, 1.52; 95% CI 1.38–1.68, p < 0.01), dyslipidemia (OR, 1.42; 95% CI 1.35–1.50, p < 0.01) and vasculitis (OR, 1.44; 95% CI 1.15–1.80, p < 0.01) were also related to the development of PD. After adjusting confounding variables, the adjusted OR of SS was 1.37 (95% CI 1.15–1.64, p < 0.01), which indicated

### Table 1. Demographic characteristics and affecting factors in the group with PD and the control group.

| Characteristics | Parkinson’s disease | Control | p-value |
|-----------------|---------------------|---------|---------|
|                 | N = 7716            | N = 75129 |         |
| N               | n       | %   | n       | %   |
| Gender          |         |      |         |      | 0.76 |
| Female          | 41992   | 50.5 | 38094   | 50.7 |      |
| Male            | 40853   | 49.5 | 37035   | 49.3 |      |
| Age, mean (SD)  | 72.8 (9.0)| 72.7 (9.0) | 0.23   |
| Sjogren’s syndrome | 1036   | 1.9  | 893     | 1.2  | < 0.001 |
| Ankylosing spondylitis | 496    | 0.8  | 433     | 0.6  | 0.009   |
| RA a            | 1373    | 1.8  | 1231    | 1.6  | 0.19    |
| SLE b           | 195     | 0.3  | 173     | 0.2  | 0.34    |
| Psoriasis       | 953     | 1.3  | 849     | 1.1  | 0.09    |
| Osteoarthritis  | 33683   | 50.5 | 29787   | 39.6 | < 0.001 |
| Diabetes        | 21499   | 34.7 | 18819   | 25.0 | < 0.001 |
| Hypertension    | 48934   | 72.1 | 43374   | 57.7 | < 0.001 |
| Atrial fibrillation | 3022  | 5.0  | 2639    | 3.5  | < 0.001 |
| ESRD c          | 3670    | 6.3  | 3182    | 4.2  | < 0.001 |
| Dyslipidemia    | 23281   | 34.6 | 20613   | 27.4 | < 0.001 |
| Vasculitis      | 684     | 1.1  | 596     | 0.8  | 0.001   |

a Rheumatoid arthritis, b Systemic Lupus Erythematosus, c End-stage renal disease

https://doi.org/10.1371/journal.pone.0175836.t001

### Table 2. Risk factors for PD.

| Variables                      | Crude OR | 95% CI | Adjusted OR | 95% CI |
|--------------------------------|----------|--------|-------------|--------|
|                                |          | Lower  | Upper       |        | Lower  | Upper       |
|                                |          |        |             |        |        |             |
| Sjogren’s syndrome             | 1.56**   | 1.30   | 1.86        | 1.38** | 1.15   | 1.66        |
| Ankylosing spondylitis         | 1.41*    | 1.08   | 1.84        | 1.20   | 0.92   | 1.57        |
| Osteoarthritis                 | 1.60**   | 1.53   | 1.69        | 1.44** | 1.37   | 1.51        |
| Diabetes                       | 1.61**   | 1.53   | 1.69        | 1.33** | 1.26   | 1.41        |
| Hypertension                   | 1.99**   | 1.89   | 2.10        | 1.71** | 1.62   | 1.81        |
| Atrial fibrillation            | 1.42**   | 1.27   | 1.59        | 1.25** | 1.12   | 1.40        |
| ESRD a                         | 1.52**   | 1.38   | 1.68        | 1.24** | 1.12   | 1.38        |
| Dyslipidemia                   | 1.42**   | 1.35   | 1.50        | 1.08** | 1.02   | 1.14        |
| Vasculitis                     | 1.44**   | 1.15   | 1.80        | 1.25   | 0.99   | 1.57        |

a End-stage renal disease, * p < 0.05, ** p < 0.01

https://doi.org/10.1371/journal.pone.0175836.t002
that SS might be associated with the increased risk for developing PD. Meanwhile, the adjusted ORs of other factors were also shown in Table 2. Except ankylosing spondylitis and vasculitis, other factors mentioned above were also related to the PD. The Forest plots for adjusted ORs were shown in Fig 2.

Discussion

In this study, SS was proposed as a risk factor for the development of PD. To the best of our knowledge, this is the first study to apply a nationwide longitudinal population-based database to estimate the relationship between SS and PD. Despite of extensive studies on PD, its underlying cause and pathogenesis still remains unknown. Complex interactions between environmental and multiple genetic factors has been shown to contribute to dopaminergic neuronal cell loss and parkinsonism, which would final establish the disease. In this study, the number of patients with history of SS in subjects who experienced PD was significantly higher than that in subjects who did not (p < 0.001). In addition, the adjusted OR for PD in patients with SS was 1.37 (95% CI 1.15–1.65, p < 0.001) as compared with that who without. Considering these results, it could be suggested that SS was a risk affecting factor for PD.

Several studies have reported that SS was associated with PD, and their results were well correlated with ours [17,18]. Our study involved a total of 143 patients who were suffering from both SS and PD. The slight large sample size may offer a good representation of ethnic Asian patients, and provide more information in approaching the connection between SS and PD.

SS is known as a disease with mononuclear lymphocytic infiltration of salivary and lacrimal glands, and it would also have a extraglandular involvement of other organs, such as lung, liver, kidney and nervous system. The most well-recognized pathogenesis is the immunologically mediated mechanisms. Autoantibodies are usually detected in patients with SS, and play

| Characteristics          | Adjusted OR (95% CI) |
|--------------------------|----------------------|
| Ankylosing spondylitis   | 1.20 (0.92 - 1.57)   |
| Sjogren’s syndrome       | 1.37 (1.15 - 1.65)   |
| Osteoarthritis           | 1.44 (1.37 - 1.51)   |
| Diabetes                 | 1.33 (1.26 - 1.41)   |
| Hypertension             | 1.71 (1.62 - 1.81)   |
| Atrial fibrillation      | 1.25 (1.12 - 1.40)   |
| End-stage renal disease  | 1.24 (1.12 - 1.38)   |
| Dyslipidemia             | 1.08 (1.02 - 1.14)   |
| Vasculitis               | 1.25 (0.99 - 1.57)   |

Fig 2. The forest plots of adjusted OR with 95% CI for the Sjogren’s syndrome (OR = 1.37, 95% CI = 1.15–1.65, p < 0.001).
an important role in connecting to connective tissue disorders. Anti-SSA and anti-SSB could be respectively found in 63% and 40% patients with SS, and they would be associated with the involvement of CNS diseases [23]. In addition, some researchers enrolled SS patients who suffered from peripheral and central nervous system abnormalities into study, and examined the antineuronal antibodies in their plasma. The results showed a higher present of these antibodies in patients with major neurologic complications than those without [24]. An immunologically mediated mechanism between SS and PD could be conjectured, in which antibodies from SS patients may directly damage the basal ganglia and contribute to PD.

Hassin-Baer S et al. [25] examined the serum of patients with both SS and PD, and found high titers of anti-beta2-glycoprotein IgG, which is an autoantibody strongly associated with anti-cardiolipin antibodies (aCL), antiphospholipid syndrome, and thromboembolic phenomena. Several previous studies have introduced that there would be a connection between aCL antibodies and PD [26–28]. Moreover, some evidences of CNS vascular lesions have been found in a proportion of cases of SS with neurologic involvement [23]. It was suggested that there might be an underlying vascular mechanism for the development of PD [25]. The role of antibodies in the pathogenesis of PD in SS is still unclear, and further studies is required. For our study, more analysis for the subjects, such as antibodies in their serum, is needed to assess the underlying mechanism and detail role of antibodies in relations between SS and PD.

There are two neurotransmitter systems in CNS, one is dopaminergic system and another is cholinergic system. Only a coordination of these systems could promise a normal physiological activity. PD primarily results from the death of dopaminergic neurons in the substantia nigra, which would break the balance between dopaminergic activity and cholinergic activity, and cause a variety of disorders. Anticholinergic drugs are commonly used to reduce cholinergic activity, and treat the symptoms of PD [29]. Oppositely, for the purpose of increasing the salivary secretion and relieving the dry symptom, cholinergic agonists are usually applied to treat the SS [30,31]. It might be conjectured that the application of drugs in treating SS would affect the development of PD, and aggravate the symptoms of PD. This assumption provides an underlying pharmacology mechanism among SS and PD, and further prospective studies are needed to warrant it.

In generally speaking, the pathogenesis of PD is multifactorial. As well correlated with previous studies [7–10,14,15], our study showed diabetes, hypertension, end-stage renal disease, dyslipidemia, atrial fibrillation and osteoarthritis were significantly connected with PD. Other than some studies [11,12], RA, SLE and psoriasis were not significant associated with PD in this study, it might be owing to the difference on sample size and ethnicity. Ankylosing spondylitis and vasculitis were not significantly related to PD after adjusting the confounding variables, it was possible due to the relative small sample size as compared with other variables. Further investigation with more sample size and other ethnic population would be needed.

Most of the PD would occur after 50 years old [5], which was similar to the demographics of our newly diagnosed PD population in terms of age. Some studies suggested that age and gender might be associated with PD [32,33]. Yet, the age and gender were not significant affecting factors for PD in this study. The possible reason for this discrepancy between previous studies and ours may be the match of age and gender for a case-control design of our study.

There are some possible limitations to the current study. First, this is a retrospective study, and the design of this study might cause a potential risk of selection bias, especially in the portion of patients. Second, the study used the ICD codes from the National Health Insurance claim database, and could be affected by the diagnostic accuracy of the database. Third, information on individual behaviors, such as smoking and alcohol consumption, and the subtypes of SS and PD are unavailable from the database. Fourth, the study results are come from the
Eastern population, and they may need to be validated in study for other ethnic population. Finally, this is a case-control study, and the effect of SS on PD over time could not be estimated, a cohort study between them is required in the future.

Conclusion
This population-based case-control study preliminarily proposed that SS was significant associated with an increased risk of PD. The pathophysiology and causality need to be further investigated in bench works or randomized clinical trials.

Supporting information
S1 Table. Operational definitions of variables.

(DOCX)

Acknowledgments
This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The authors had permission from the Department of Health and managed to use those data for analysis with full access to all of the data in the study. MC Wu and JC Wei take full responsibility for the integrity of the data and the accuracy of the data analysis.

Author Contributions
Conceptualization: JCCW MCW XX.
Data curation: JCCW MCW XX JYC.
Formal analysis: YHW JYC LCL.
Investigation: JCCW MCW XX.
Methodology: MCW XX SMC YST JYC YHW LCL CMC.
Project administration: JCCW JYC.
Resources: JCCW YHW JYC LCL.
Software: YHW JYC LCL.
Supervision: JCCW YST.
Validation: SMC YST JYC YHW LCL CMC.
Visualization: MCW XX.
Writing — original draft: MCW XX.
Writing — review & editing: MCW XX SMC YST JYC YHW LCL CMC.

References
1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348:1356–1364. https://doi.org/10.1056/NEJM2003ra020003 PMID: 12672864
2. Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA. Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord. 2006; 21:446–455. https://doi.org/10.1002/mds.20685 PMID: 16161155

3. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1998; 50:318–318. PMID: 9484345

4. Liu WM, Wu RM, Lin JW, Liu YC, Chang CH, Lin CH. Time trends in the prevalence and incidence of Parkinson’s disease in Taiwan: A nationwide, population-based study. J Formos Med Assoc. 2016; 115:531–538. https://doi.org/10.1016/j.jfma.2015.05.014 PMID: 26123636

5. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. The Lancet Neurol. 2006; 5:525–535. https://doi.org/10.1016/S1474-4422(06)70471-9 PMID: 16713924

6. Okun MS. Deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2012; 367:1529–1538. https://doi.org/10.1056/NEJMct1208070 PMID: 23075179

7. Zhang P, Tian B. Metabolic syndrome: an important risk factor for Parkinson’s disease. Oxid Med Cell Longev. 2014; 2014:1–7.

8. Wang IK, Lin CL, Wu YY, Chou CY, Lin SY, Liu JH, et al. Increased risk of Parkinson’s disease in patients with end-stage renal disease: a retrospective cohort study. Neuroepidemiology. 2014; 42:204–210. https://doi.org/10.1159/000358921 PMID: 24751820

9. Qiu C, Hu G, Kvipelto M, Laatikainen T, Antikainen R, Fratiglioni L, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: the national FINRISK study. Hypertension. 2011; 57:1094–1100. https://doi.org/10.1161/HYPERTENSIONAHA.111.171249 PMID: 21536985

10. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BHC. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004; 44:2117–2124. https://doi.org/10.1016/j.jacc.2004.08.053 PMID: 15582307

11. Kogure T, Tatsumi T, Kaneko Y, Okamoto K. Rheumatoid arthritis accompanied by Parkinson disease. J Clin Rheumatol. 2008; 14:192–193.

12. Garcia-Moreno JM, Chacón J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord. 2002; 17:1329–1335. https://doi.org/10.1002/mds.10288 PMID: 12465077

13. Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korb L, Olsen JH. Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology. 2009; 73:1462–1468. https://doi.org/10.1212/01.wnl.0000335762.25088.a7 PMID: 19776374

14. Sheu JJ, Wang KH, Lin HC, Huang CC. Psoriasis is associated with an increased risk of parkinsonism: a population-based 5-year follow-up study. J Am Acad Dermatol. 2013; 68:992–999. https://doi.org/10.1016/j.jaad.2012.12.961 PMID: 23374233

15. Rugbjerg K, Friis S, Mørgensen TL, Ritz B, Korb L, Olsen JH. Risk for Parkinson’s disease among patients with osteoarthritis: a Danish cohort study. Mov Disord. 2010; 25:2355–2360. https://doi.org/10.1002/mds.23274 PMID: 20721917

16. Fabiani G, Teive HAG, Germiniani FMB, Sa DS, Werneck LC. Reversible parkinsonian syndrome in systemic and brain vasculitis. Mov Disord. 2002; 17:601–604. https://doi.org/10.1002/mds.10029 PMID: 12112215

17. Kchaou M, Ben Ali N, Hmida I, Fray S, Jamoussi H, Jalleli M, et al. Parkinsonism and Sjögren’s Syndrome: A Fortuitous Association or a Shared Immunopathogenesis? Case Rep Med. 2015; 2015:1–4.

18. Walker RH, Spiera H, Brin MF, Olanow CW. Parkinsonism associated with Sjögren’s syndrome: three cases and a review of the literature. Mov Disord. 1999; 14:262–268. PMID: 10091620

19. Qin B, Wang J, Yang Z, Yang M, Mao N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74:1983–1989. https://doi.org/10.1136/annrheumdis-2014-205375 PMID: 24938285

20. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebling C, Cervera R. Pathophysiology of Sjögren’s syndrome. Arch Med Res. 2006; 37:921–932. https://doi.org/10.1016/j.arcmed.2006.08.002 PMID: 17045106

21. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferniby D, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine. 2004; 83:280–291. PMID: 15342972

22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55:181–184. PMID: 1564476

23. Alexander EL. Neurologic disease in Sjögren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am. 1993; 19:869–908. PMID: 8265827
24. Moll J, Markusse HM, Pijnenburg JJ, Vecht CJ, Henzen-Logmans SC. Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome. Neurology. 1993; 43:2574–2574. PMID: 8255460

25. Hassin-Baer S, Levy Y, Langevitz P, Nakar S, Ehrenfeld M. Anti-β2-glycoprotein I in Sjögren’s syndrome is associated with parkinsonism. Clin Rheumatol. 2007; 26:743–747. https://doi.org/10.1007/s10067-006-0398-8 PMID: 17057945

26. Miyoshi Y, Atsumi T, Kitagawa H, Ogura N, Amasaki Y, Tsutsumi A, et al. Parkinson-like symptoms as a manifestation of systemic lupus erythematosus. Lupus. 1993; 2:199–201. https://doi.org/10.1177/096120339300200314 PMID: 8369813

27. Shahar E, Goshen E, Tauber Z, Lahat E. Parkinsonian syndrome complicating systemic lupus erythematosus. Pediatr Neurol. 1998; 18:456–458. PMID: 9650692

28. Mochizuki H, Okano M, Masaki T, Nagata N, Kamakura K. A case of Sjögren’s syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism. Rinsho Shinkeigaku. 1997; 37:57–59. PMID: 9146077

29. Brooks DR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999; 2:39–46. PMID: 10952768

30. Chambers MS. Sjögren’s syndrome. ORL Head Neck Nurs. 2004; 22:22–30; quiz 2–3. PMID: 15617317

31. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren’s Syndrome. Clin Rev Allergy Immunol. 2007; 32:284–291. https://doi.org/10.1007/s12016-007-8008-3 PMID: 17992595

32. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157:1015–1022. PMID: 12777365

33. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol. 1992; 49:492–497. PMID: 1580811